The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
News|Articles|August 31, 2026
2026 FDA Approvals: Infectious Disease Vaccines
Author(s)John Parkinson
Here is a comprehensive list of vaccines approved this year as well as background information on the clinical data for each of them.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) issued vaccine approvals and expanded indications this year, spanning RSV, influenza, pneumococcal disease, and COVID-19. GSK's Arexvy gained clearance for younger at-risk adults, Moderna secured approval for its first mRNA flu vaccine, and Merck's Capvaxive expanded into pediatric populations with underlying conditions.
Related to this article
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement